scispace - formally typeset
K

Koert J. Stittelaar

Researcher at Erasmus University Rotterdam

Publications -  78
Citations -  3469

Koert J. Stittelaar is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Virus & Vaccination. The author has an hindex of 29, co-authored 74 publications receiving 2783 citations. Previous affiliations of Koert J. Stittelaar include Centre for Health Protection.

Papers
More filters
Journal ArticleDOI

Animal models for COVID-19.

César Muñoz-Fontela, +64 more
- 23 Sep 2020 - 
TL;DR: The findings of a World Health Organization expert working group that is developing animal models to test vaccines and therapeutic agents for the treatment of COVID-19, and their relevance for preclinical testing, are reviewed.
Journal ArticleDOI

Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus

TL;DR: The MVA-based smallpox vaccine protected macaques against a lethal respiratory challenge with monkeypox virus and is therefore an important candidate for the protection of humans against smallpox.
Journal ArticleDOI

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques

TL;DR: The data suggest that MVA can safely be used as a basis for recombinant human vaccines, and that it is also safe for use in immunocompromised individuals.
Journal ArticleDOI

Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection

TL;DR: Comparing the effectiveness of post-exposure smallpox vaccination and antiviral treatment after lethal intratracheal infection of cynomolgus monkeys with monkeypox virus shows that adequate preparedness for a biological threat involving smallpox should include the possibility of treating exposed individuals with antiviral compounds such as cidofovir or other selective anti-poxvirus drugs.
Journal ArticleDOI

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.

TL;DR: Protection data in a stringent challenge model in association with an excellent clinical profile highlight the potential of this adjuvanted H5N1 candidate vaccine as an effective tool in pandemic preparedness.